Author:
Sarah K. Obay ,Ali N. Wannas ,Rana A. Ghaleb
Abstract
Though chemotherapy is the major strategy to manage patients with advanced-stage colorectal cancer (CRC), the main challenge is the progression of CRC despite using combination of different chemotherapeutic agents. So, to overcome this challenge, a new class
Of therapy was developed naming “Targeted-therapy”. This class of drugs aim to target specific overexpressed or aberrant enzyme, receptor, or gene that have critical role in the growth and survival of colorectal cancerous cells. So that, by using combination of traditional strategy (chemotherapy) and targeted-drug, this will lead to improve survival and prevent the progression of advanced CRC
Publisher
Al Mustansiriyah University - College of Pharmacy
Reference51 articles.
1. - World Health Organization (WHO) and the International Agency for Research on Cancer (IARC). Iraqi Cancer incidence and mortality. Iraq - Glob Cancer Obs Globocan 2020. 2020;2020–1.
2. - Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17(2):111–30.
3. - Wu C. Systemic Therapy for Colon Cancer. Surg Oncol Clin N Am. 2018;27(2):235–42. Available from: https://doi.org/10.1016/j.soc.2017.11.001
4. - Lupinacci RM, Andraus W, De Paiva Haddad LB, Carneiro D′Albuquerque LA, Herman P. Simultaneous laparoscopic resection of primary colorectal cancer and associated liver metastases: A systematic review. Tech Coloproctol. 2014;18(2):129–35.
5. - van der Geest LGM, Lam-Boer J, Koopman M, Verhoef C, Elferink MAG, de Wilt JHW. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457–65.